세프트리악손나트륨 : 세계 시장 점유율과 순위, 총판매량 및 수요 예측(2025-2031년)

The global market for Ceftriaxone Sodium was estimated to be worth US$ 250 million in 2024 and is forecast to a readjusted size of US$ 207 million by 2031 with a CAGR of -2.7% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Ceftriaxone Sodium cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

Ceftriaxone Sodium is a broad-spectrum third-generation cephalosporin antibiotic that exerts bactericidal effects by inhibiting bacterial cell wall synthesis. It is indicated for the treatment of respiratory tract infections, urinary and reproductive system infections, skin and soft tissue infections, sepsis, and meningitis. The drug features a long half-life, sustained action, good tolerability, and can be administered via intravenous or intramuscular injection, making it widely applicable in clinical practice. In recent years, with increasing antibiotic resistance and the ongoing global burden of infectious diseases, the demand for ceftriaxone sodium in hospitals, community healthcare settings, and emergency infection control has grown steadily. Manufacturers have also optimized production processes and integrated raw materials to improve efficiency and product quality stability.In this report, we study the Ceftriaxone Sodium API.In 2024, global Ceftriaxone Sodium production reached approximately 2766 mt, with an average global market price of around US$ 94 per kg.

The global burden of infectious diseases continues to rise, particularly in developing countries and regions with aging populations, driving steady growth in demand for antibiotics and providing a strong growth impetus for the ceftriaxone sodium market. Governments are promoting policies for rational antibiotic use, insurance coverage, and updated clinical guidelines, encouraging hospitals to procure high-quality antibiotics. Annual reports indicate that leading pharmaceutical manufacturers continue to invest in raw material integration, capacity expansion, and development of new formulations to ensure supply stability and product diversity. Brokerage reports highlight that antimicrobial resistance control, community infection management, and standardized clinical usage trends will further increase market penetration of ceftriaxone sodium in hospitals and primary care facilities.

The ceftriaxone sodium industry faces challenges such as raw material price volatility, complex production processes, and strict international quality standards. Annual reports reveal that key raw materials are partially imported, and supply chain fluctuations may impact production stability. Antibiotic resistance issues, strengthened regulatory oversight, and centralized procurement or price caps may pressure mid- to low-end product margins. Cross-border market expansion must also navigate registration approvals, market access, and regulatory differences, increasing operational risks for enterprises.

Downstream demand from hospitals, community healthcare institutions, and public health departments shows stable growth with structural optimization. Clinicians prefer formulations suitable for long-term storage, flexible dosing regimens, and both intravenous and intramuscular administration to address different infection types and emergency scenarios. Brokerage reports indicate that with the promotion of rational antibiotic use, hospital medication standardization, and digital drug management systems, ceftriaxone sodium is expected to achieve higher clinical adherence and inventory efficiency, while high-end formulations and novel extended-release products may become key points of market differentiation in the future.

This report aims to provide a comprehensive presentation of the global market for Ceftriaxone Sodium, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Ceftriaxone Sodium by region & country, by Type, and by Application.

The Ceftriaxone Sodium market size, estimations, and forecasts are provided in terms of sales volume (MT) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ceftriaxone Sodium.

Market Segmentation

By Company

• Shandong Ruiying
• Qilu Antibiotics
• Nectar Lifesciences
• Kelun
• United Laboratories
• Aurobindo Pharma
• Orchid Pharma
• Medya Pharma
• REYOUNG
• LKPC
• ACS Dobfar
• NCPC
• Dawnrays
• Kopran

Segment by Type

• ChP
• USP
• EP

Segment by Application

• Single Injection
• Compound Injection

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Ceftriaxone Sodium manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Ceftriaxone Sodium in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Ceftriaxone Sodium in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Ceftriaxone Sodium Product Introduction
• 1.2 Global Ceftriaxone Sodium Market Size Forecast
  • 1.2.1 Global Ceftriaxone Sodium Sales Value (2020-2031)
  • 1.2.2 Global Ceftriaxone Sodium Sales Volume (2020-2031)
  • 1.2.3 Global Ceftriaxone Sodium Sales Price (2020-2031)
• 1.3 Ceftriaxone Sodium Market Trends & Drivers
  • 1.3.1 Ceftriaxone Sodium Industry Trends
  • 1.3.2 Ceftriaxone Sodium Market Drivers & Opportunity
  • 1.3.3 Ceftriaxone Sodium Market Challenges
  • 1.3.4 Ceftriaxone Sodium Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Ceftriaxone Sodium Players Revenue Ranking (2024)
• 2.2 Global Ceftriaxone Sodium Revenue by Company (2020-2025)
• 2.3 Global Ceftriaxone Sodium Players Sales Volume Ranking (2024)
• 2.4 Global Ceftriaxone Sodium Sales Volume by Company Players (2020-2025)
• 2.5 Global Ceftriaxone Sodium Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Ceftriaxone Sodium Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Ceftriaxone Sodium Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Ceftriaxone Sodium
• 2.9 Ceftriaxone Sodium Market Competitive Analysis
  • 2.9.1 Ceftriaxone Sodium Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Ceftriaxone Sodium Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Ceftriaxone Sodium as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 ChP
  • 3.1.2 USP
  • 3.1.3 EP
• 3.2 Global Ceftriaxone Sodium Sales Value by Type
  • 3.2.1 Global Ceftriaxone Sodium Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Ceftriaxone Sodium Sales Value, by Type (2020-2031)
  • 3.2.3 Global Ceftriaxone Sodium Sales Value, by Type (%) (2020-2031)
• 3.3 Global Ceftriaxone Sodium Sales Volume by Type
  • 3.3.1 Global Ceftriaxone Sodium Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Ceftriaxone Sodium Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Ceftriaxone Sodium Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Ceftriaxone Sodium Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Single Injection
  • 4.1.2 Compound Injection
• 4.2 Global Ceftriaxone Sodium Sales Value by Application
  • 4.2.1 Global Ceftriaxone Sodium Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Ceftriaxone Sodium Sales Value, by Application (2020-2031)
  • 4.2.3 Global Ceftriaxone Sodium Sales Value, by Application (%) (2020-2031)
• 4.3 Global Ceftriaxone Sodium Sales Volume by Application
  • 4.3.1 Global Ceftriaxone Sodium Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Ceftriaxone Sodium Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Ceftriaxone Sodium Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Ceftriaxone Sodium Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Ceftriaxone Sodium Sales Value by Region
  • 5.1.1 Global Ceftriaxone Sodium Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Ceftriaxone Sodium Sales Value by Region (2020-2025)
  • 5.1.3 Global Ceftriaxone Sodium Sales Value by Region (2026-2031)
  • 5.1.4 Global Ceftriaxone Sodium Sales Value by Region (%), (2020-2031)
• 5.2 Global Ceftriaxone Sodium Sales Volume by Region
  • 5.2.1 Global Ceftriaxone Sodium Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Ceftriaxone Sodium Sales Volume by Region (2020-2025)
  • 5.2.3 Global Ceftriaxone Sodium Sales Volume by Region (2026-2031)
  • 5.2.4 Global Ceftriaxone Sodium Sales Volume by Region (%), (2020-2031)
• 5.3 Global Ceftriaxone Sodium Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Ceftriaxone Sodium Sales Value, 2020-2031
  • 5.4.2 North America Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Ceftriaxone Sodium Sales Value, 2020-2031
  • 5.5.2 Europe Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Ceftriaxone Sodium Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Ceftriaxone Sodium Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Ceftriaxone Sodium Sales Value, 2020-2031
  • 5.7.2 South America Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Ceftriaxone Sodium Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Ceftriaxone Sodium Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Ceftriaxone Sodium Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Ceftriaxone Sodium Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Ceftriaxone Sodium Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.3.2 United States Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.4.2 Europe Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.5.2 China Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.6.2 Japan Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.7.2 South Korea Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Ceftriaxone Sodium Sales Value, 2020-2031
  • 6.9.2 India Ceftriaxone Sodium Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Ceftriaxone Sodium Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Shandong Ruiying
  • 7.1.1 Shandong Ruiying Company Information
  • 7.1.2 Shandong Ruiying Introduction and Business Overview
  • 7.1.3 Shandong Ruiying Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Shandong Ruiying Ceftriaxone Sodium Product Offerings
  • 7.1.5 Shandong Ruiying Recent Development
• 7.2 Qilu Antibiotics
  • 7.2.1 Qilu Antibiotics Company Information
  • 7.2.2 Qilu Antibiotics Introduction and Business Overview
  • 7.2.3 Qilu Antibiotics Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Qilu Antibiotics Ceftriaxone Sodium Product Offerings
  • 7.2.5 Qilu Antibiotics Recent Development
• 7.3 Nectar Lifesciences
  • 7.3.1 Nectar Lifesciences Company Information
  • 7.3.2 Nectar Lifesciences Introduction and Business Overview
  • 7.3.3 Nectar Lifesciences Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Nectar Lifesciences Ceftriaxone Sodium Product Offerings
  • 7.3.5 Nectar Lifesciences Recent Development
• 7.4 Kelun
  • 7.4.1 Kelun Company Information
  • 7.4.2 Kelun Introduction and Business Overview
  • 7.4.3 Kelun Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Kelun Ceftriaxone Sodium Product Offerings
  • 7.4.5 Kelun Recent Development
• 7.5 United Laboratories
  • 7.5.1 United Laboratories Company Information
  • 7.5.2 United Laboratories Introduction and Business Overview
  • 7.5.3 United Laboratories Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 United Laboratories Ceftriaxone Sodium Product Offerings
  • 7.5.5 United Laboratories Recent Development
• 7.6 Aurobindo Pharma
  • 7.6.1 Aurobindo Pharma Company Information
  • 7.6.2 Aurobindo Pharma Introduction and Business Overview
  • 7.6.3 Aurobindo Pharma Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Aurobindo Pharma Ceftriaxone Sodium Product Offerings
  • 7.6.5 Aurobindo Pharma Recent Development
• 7.7 Orchid Pharma
  • 7.7.1 Orchid Pharma Company Information
  • 7.7.2 Orchid Pharma Introduction and Business Overview
  • 7.7.3 Orchid Pharma Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Orchid Pharma Ceftriaxone Sodium Product Offerings
  • 7.7.5 Orchid Pharma Recent Development
• 7.8 Medya Pharma
  • 7.8.1 Medya Pharma Company Information
  • 7.8.2 Medya Pharma Introduction and Business Overview
  • 7.8.3 Medya Pharma Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Medya Pharma Ceftriaxone Sodium Product Offerings
  • 7.8.5 Medya Pharma Recent Development
• 7.9 REYOUNG
  • 7.9.1 REYOUNG Company Information
  • 7.9.2 REYOUNG Introduction and Business Overview
  • 7.9.3 REYOUNG Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 REYOUNG Ceftriaxone Sodium Product Offerings
  • 7.9.5 REYOUNG Recent Development
• 7.10 LKPC
  • 7.10.1 LKPC Company Information
  • 7.10.2 LKPC Introduction and Business Overview
  • 7.10.3 LKPC Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 LKPC Ceftriaxone Sodium Product Offerings
  • 7.10.5 LKPC Recent Development
• 7.11 ACS Dobfar
  • 7.11.1 ACS Dobfar Company Information
  • 7.11.2 ACS Dobfar Introduction and Business Overview
  • 7.11.3 ACS Dobfar Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 ACS Dobfar Ceftriaxone Sodium Product Offerings
  • 7.11.5 ACS Dobfar Recent Development
• 7.12 NCPC
  • 7.12.1 NCPC Company Information
  • 7.12.2 NCPC Introduction and Business Overview
  • 7.12.3 NCPC Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 NCPC Ceftriaxone Sodium Product Offerings
  • 7.12.5 NCPC Recent Development
• 7.13 Dawnrays
  • 7.13.1 Dawnrays Company Information
  • 7.13.2 Dawnrays Introduction and Business Overview
  • 7.13.3 Dawnrays Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Dawnrays Ceftriaxone Sodium Product Offerings
  • 7.13.5 Dawnrays Recent Development
• 7.14 Kopran
  • 7.14.1 Kopran Company Information
  • 7.14.2 Kopran Introduction and Business Overview
  • 7.14.3 Kopran Ceftriaxone Sodium Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Kopran Ceftriaxone Sodium Product Offerings
  • 7.14.5 Kopran Recent Development

8 Industry Chain Analysis

• 8.1 Ceftriaxone Sodium Industrial Chain
• 8.2 Ceftriaxone Sodium Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Ceftriaxone Sodium Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Ceftriaxone Sodium Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer